Skip to main content
All lobbying clients

AMGEN USA INC.

Lobbying client · District of Columbia · filed 2025 to 2026

Biotechnology company.

$1,970,000 Reported spend
35 Filings counted
5 Outside firms hired
8 Bills named

Spend is reported income plus in-house expenses across 35 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 5 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as AMGEN USA INC, AMGEN USA, INC.

 Who filed for this client 5

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 8
  • H.R. 1492
    To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and bi…
    7 filings
  • S. 1040
    Drug Competition Enhancement Act
    7 filings
  • S. 1041
    Affordable Prescriptions for Patients Act
    7 filings
  • H. Con. Res. 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…
    2 filings
  • H.R. 2882
    Further Consolidated Appropriations Act, 2024
    1 filing
  • H.R. 1
    One Big Beautiful Bill Act
    1 filing
  • H.R. 7148
    Consolidated Appropriations Act, 2026
    1 filing
  • S. Con. Res. 7
    An original concurrent resolution setting forth the congressional budget for the United States Government for…
    1 filing
 Reported by year 2 years
  • 2026 $810,000 15 filings
  • 2025 $1,160,000 20 filings
 Issues lobbied 8

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 5
  • SENATE 35
  • HOUSE OF REPRESENTATIVES 31
  • Food & Drug Administration (FDA) 7
  • Natl Economic Council (NEC) 7
  • Treasury, Dept of 2
 Recent filings 35 total
Q3 report
MARSHALL & POPP, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
ACG ADVOCACY
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
AKIN GUMP STRAUSS HAUER & FELD
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
FORBES-TATE
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 18, 2026
View →
Q3 report
OGR
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 16, 2026
View →
Q2 report
FORBES-TATE
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
AKIN GUMP STRAUSS HAUER & FELD
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
ACG ADVOCACY
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 17, 2026
View →
Q2 report
OGR
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 16, 2026
View →
Q2 report
MARSHALL & POPP, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 9, 2026
View →
Q1 report
AKIN GUMP STRAUSS HAUER & FELD
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View →
Q1 report
OGR
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 19, 2026
View →
Q1 report
FORBES-TATE
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $80,000 income · posted Apr 17, 2026
View →
Q1 report
MARSHALL & POPP, LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 17, 2026
View →
Q1 report
ACG ADVOCACY
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 9, 2026
View →
Q4 report
ACG ADVOCACY
4th Quarter 2025 (Oct 1 - Dec 31) · Senate · $50,000 income · posted Jan 20, 2026
View →
Q4 report
AKIN GUMP STRAUSS HAUER & FELD
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View →
Q4 report
FORBES-TATE
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $80,000 income · posted Jan 18, 2026
View →
Q4 report
OGR
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 17, 2026
View →
Q4 report
MARSHALL & POPP, LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $60,000 income · posted Jan 16, 2026
View →

Showing the 20 most recent of 35 filings. Search the explorer for "AMGEN USA INC.".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem